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Anti-Mu¨llerian hormone (AMH) concentrations correlate with
the number of antral follicles as well as age and constitute an
endocrine marker for ovarian aging. In normogonadotropic
anovulatory infertile women [World Health Organization
(WHO) class 2], the number of early antral follicles is usually
increased. To investigate whether AMH concentrations are
increased, serum levels in 128 WHO 2 women were compared
with those in 41 normoovulatory premenopausal women of
similar age.
Serum AMH concentrations are significantly (P < 0.001)
elevated in WHO 2 patients [median, 7.6 g/liter (range, 0.1–
40.0)], compared with controls [median, 2.1 g/liter (0.1–7.4)].
In 106 patients presenting with polycystic ovaries (PCOs) (>12
follicles/ovary measuring 2–9 mm and/or an ovarian volume >
10 ml), AMH levels were elevated [9.3 g/liter (1.8–40.0)], com-
pared with 22 patients without PCOs [6.4 g/liter (0.1–22.1)]
(P < 0.0001). In WHO 2 patients, AMH concentrations corre-
lated with features characteristic for polycystic ovary syn-
drome such as LH concentrations (r  0.331; P  0.0001), tes-
tosterone levels (r  0.477, P  0.0001), mean ovarian volume
(r 0.421; P 0.0001), and the number of ovarian follicles (r
0.308; P 0.0001). AMH levels correlated well with age in WHO
2 patients (r  0.248; P  0.002) as well as in controls (r 
0.465; P  0.005). However, the relative decline in AMH with
age is less pronounced in WHO 2 patients. In a subset of pa-
tients no significant correlation was found between AMH se-
rum concentrations and the FSH response dose, the duration
of stimulation, and the total number of ampoules of FSH used.
In conclusion, serum AMH concentrations are elevated in
WHO 2 women, especially in those patients exhibiting PCOs.
Because AMH concentrations correlated well with other clin-
ical, endocrine, and ultrasound markers associated with poly-
cystic ovary syndrome, AMH may be used as a marker for the
extent of the disease. A less pronounced AMH decrease over
time in these women may suggest retarded ovarian aging. The
latter hypothesis, however, should be confirmed by longitu-
dinal studies. (J Clin Endocrinol Metab 89: 318–323, 2004)
THE DIMERIC GLYCOPROTEIN anti-Mu¨llerian hor-mone (AMH), also referred to as Mu¨llerian-inhibiting
substance, is a member of the TGF superfamily (1). During
fetal sex differentiation, AMH is produced by Sertoli cells in
the male, in which it induces degeneration of the Mu¨llerian
ducts (2). In females, AMH is expressed only postnatally by
the ovary, and until recently its function in the female re-
productive tract was unknown (3, 4).
Female AMH null mice were reported to be fertile and
produced normal-sized litters (5). However, ovaries of AMH
null mice as well as female mice heterozygous for the AMH
null mutation contained less primordial follicles and more
growing follicles, compared with their wild-type littermates
(6). In addition, AMH was able to inhibit the initiation of
primordial follicle growth in cultured neonatal mouse ova-
ries (6) and stimulate growth of rat preantral follicles (7).
Hence, AMH appears to regulate early follicle development
directly. Furthermore, the absence of AMH has been shown
to enhance FSH-induced follicle growth in female mice (8).
Recently serum AMH levels have been shown to decrease
over time in young normoovulatory women, whereas other
markers associated with ovarian aging did not change dur-
ing this time interval (9). Although AMH concentrations did
correlate with age and FSH, AMH serum levels were most
strongly associated with the number of antral follicles. There-
fore, AMH might represent a sensitive marker for ovarian
aging (10). Indeed, it has been shown that poor response
during in vitro fertilization, indicative of a diminished ovar-
ian reserve (11), is associated with reduced baseline serum
AMH concentrations (12, 13).
Chronic anovulation constitutes a major (20–25%) pro-
portion of infertile couples (14, 15). According to the World
Health Organization (WHO), approximately 80% of patients
suffering from chronic anovulation present with serum FSH
levels within the normal range along with normal endoge-
nous estrogen activity. These women are classified as having
normogonadotropic normoestrogenic anovulatory infertil-
ity, more commonly referred to as WHO class 2 (16). Because
etiologic factors underlying this condition may vary from
one patient to another, WHO 2 anovulatory women includ-
ing those with polycystic ovary syndrome (PCOS) constitute
a notoriously heterogeneous population (17). In WHO 2 pa-
tients, the number of small antral follicles is generally in-
creased due to disturbed dominant follicle selection (18).
Abbreviations: AD, Androstenedione; AMH, anti-Mu¨llerian hor-
mone; E2, estradiol; PCO, polycystic ovary; PCOS, PCO syndrome; T,
testosterone.
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Because AMH is predominantly expressed by small follicles
in mice (4) as well as in the human (19), AMH serum con-
centrations may be increased in patients with polycystic ova-
ries (PCOs). Indeed, in PCOS patients exhibiting the classical
features of the syndrome, AMH levels were found to be
elevated, compared with normal controls (20). The current
study was designed to evaluate AMH as a clinically relevant
marker for the extent of ovarian dysfunction in WHO 2
anovulatory women, with or without PCOs.
Subjects and Methods
Subjects
The local Medical Ethics Review Committee approved this study, and
informed consent was obtained from all participants. Included in the
present study were 128 patients attending our fertility clinic between
1994 and 1999 with the following: 1) infertility; 2) oligomenorrhea (in-
terval between periods35 d) or amenorrhea (absence of vaginal bleed-
ing for at least 6 months); 3) serum FSH concentrations within normal
limits (1–10 IU/liter) (21); 4) positive withdrawal bleeding after pro-
gestogen administration in case of amenorrhea; and 5) age between 19
and 41 yr. Standardized initial screening [clinical investigation, trans-
vaginal ultrasound, and fasting blood withdrawal] was performed on a
random day between 0900 and 1100 h, irrespective of the interval be-
tween blood sampling and the preceding bleeding, as previously de-
scribed (22). A subgroup of these patients was diagnosed with PCOS due
to hyperandrogenemia and an increased follicle number and/or ovarian
volume. Hyperandrogenemia was defined as an elevated (4.5) free
androgen index (testosterone  100/ SHBG). Similarly, an increased
follicle number was defined as 12 follicles or more per ovary measuring
2–9 mm, and the ovarian volume was considered to be increased above
10 ml (15).
For sonographic imaging, we used a 6.5 MHz vaginal transducer
(model EUB-415, Hitachi Medical Corp., Tokyo, Japan). The ovaries
were localized and scanned as described previously (23). Ovarian vol-
ume, stroma echogenicity (arbitrarily scored from 1 to 3 per ovary), and
the mean follicle number were assessed as described earlier (15). Women
exhibiting PCOs had either an increased ovarian volume (10 ml) or an
increased number of follicles (12 follicles measuring 2–9 mm in at least
one ovary).
The control group consisted of 41 healthy volunteers selected by
advertisement and paid for participation as previously published (21).
Inclusion criteria were a regular menstrual cycle (26–30 d), age of 20–36
yr, normal body mass index (18–25 kg/m2), and no previous use of
medication or oral contraceptives during at least 3 months before the
study. Transvaginal ultrasound and blood sampling was performed
during the early follicular phase (cycle d 3, 4, or 5).
Ovulation induction treatment
In a subgroup of WHO 2 women (those who failed to ovulate or
conceive after clomiphene citrate treatment), gonadotropin treatment
was commenced within 3–5 d after initiation of a spontaneous or pro-
gestogen-induced withdrawal bleeding. Patients received daily sc in-
jections of recombinant FSH (Gonal-F, Ares-Serono, Geneva, Switzer-
land). During all first cycles, a low-dose step-up protocol was used with
a starting dose of FSH of one ampoule (75 IU) per day. The daily dose
was increased by 1⁄2 ampoule if ovarian response (at least one follicle of
at least 10 mm) was absent after 14 d. Thereafter the dose was increased
by 1⁄2 ampoule every 7 d if required. The FSH response dose was defined
as the dose at which an ovarian response was observed (24). In case a
sufficient ovarian response was observed, the dose was kept constant
until administration of 5000 IU human chorionic gonadotropin (Profasi,
Ares-Serono).
Hormone assays
Blood samples were obtained by venepuncture and processed within
2 h after withdrawal. Serum was stored at20 C and assayed for AMH,
LH, FSH, androstenedione (AD), testosterone (T), SHBG, inhibin B, and
estradiol (E2). Serum AMH levels were assessed using an ultrasensitive
immunoenzymometric assay (Immunotech-Coulter, Marseilles, France),
as described elsewhere (9). The limit of detection (defined as blank 3
sd of the blank) amounted to 0.05 g/liter. For quality control, samples
of pooled serum with high and low levels of AMH were assayed in all
separate assays. Intra- and interassay coefficients of variation were less
then 5% and 8%, respectively.
Serum levels of LH, FSH, and SHBG were measured using lumines-
cence-based immunoassays (Immulite, Diagnostic Products Corp., Los
Angeles, CA), whereas serum E2, T, and AD levels were measured using
coated-tube RIAs provided by the same supplier. Intra- and interassay
coefficients of variation were less than 5% and 15% for LH, less than 3%
and 8% for FSH, less than 8% and 11% for AD, less than 3% and 5% for
T, less than 5% and 7% for E2, and less than 4% and 5% for SHBG,
respectively.
Dimeric inhibin B levels were assessed using an immunoenzymo-
metric assay obtained from Serotec (Oxford, UK), as described previ-
ously (21). The detection limit of the assay, defined as the amount of
inhibin equivalent with the signal of the blank3 sds of this signal, was
3.4 ng/liter. Intra- and interassay coefficients of variation for inhibin B
were less than 9% and 15%, respectively.
Data analysis
Statistical analysis was performed using a commercially available
software package (SPSS, SPSS Inc., Chicago, IL). Data were analyzed for
normal distribution. Data are presented as the mean  sd if distributed
normally or otherwise as the median and range. To determine differ-
ences between groups, Mann-Whitney U or Kruskal-Wallis tests were
used if data were not normally distributed. In case data were normally
distributed, Student’s t test or ANOVA was used. Correlations were
expressed as Spearman’s correlation coefficients. Regression statistics
were applied to assess the differences in decline of parameters in time.
P  0.05 was considered to be statistically significant.
Results
General clinical characteristics and endocrine data as well
as ultrasound findings in controls and patients are summa-
rized in Table 1. Briefly, patients were comparable with con-
trol subjects as far as age was concerned. Endocrine param-
eters in control subjects were all well within the normal range
for regularly cycling women. Similarly ultrasound scans re-
vealed normal follicle counts in both ovaries in these
volunteers.
WHO 2 patients were either oligo- or amenorrheic, with a
median cycle duration of 75 d, being significantly different
(P  0.001) from controls. The body mass index was signif-
icantly different in WHO 2 women, compared with controls
(P  0.01). WHO 2 women presented with elevated LH and
T and more PCOs on ultrasound scanning.
AMH levels were significantly (P  0.001) different be-
tween controls (median 2.1 g/liter; range, 0.1–7.1 g/liter)
and WHO 2 patients (median 7.6 g/liter; range 0.1–40.0
g/liter). When WHO 2 women were categorized into those
with and without PCOs (12 follicles measuring between 2
and 9 mm and/or ovarian volume10 ml), AMH levels were
significantly higher (9.3 g/liter; range 1.8–40.0 g/liter) in
PCO patients, compared with non-PCO (6.4 g/liter; range
0.1–22.1 g/liter; P 0.001) and controls (2.1 g/liter; range
0.1–7.1 g/liter; P  0.001) (Fig. 1).
There was a significant (r  0.465; P  0.002) negative
correlation between age and AMH levels in control subjects.
Similarly, a significant negative correlation was found in
WHO 2 patients (r  0.248; P  0.001). The decrease in
AMH levels with increasing age was significantly (P 0.001)
different in WHO 2 patients, compared with controls (Fig. 2).
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In WHO 2 patients, AMH levels were significantly corre-
lated with cycle duration (r 0.203; P 0.05), LH (r 0.331;
P 0.001), T (r 0.477; P 0.001), AD (r 0.321; P 0.001),
free androgen index (r  0.224; P  0.01), mean ovarian
volume (r 0.421; P 0.001), and mean follicle number (r
0.308; P  0.001) but not with inhibin B levels (Fig. 3).
In 79 WHO 2 patients who previously failed clomiphene
citrate ovulation induction (75%), data with regard to ovu-
lation induction outcome using gonadotropins were avail-
able. There was no significant correlation between AMH
serum levels and the FSH response dose, being defined as the
dose of exogenous FSH at which the first follicle of 10 mm
or larger emerged (r  0.147; P  0.200; data not shown).
Similarly, there was no correlation between AMH serum
concentrations and the duration of stimulation (in days) or
the total number of ampoules FSH used (data not shown).
Discussion
The present study clearly shows that AMH levels are in-
creased in normogonadotropic anovulatory infertile pa-
tients. The subgroup of WHO 2 women exhibiting PCOs
presents with the highest AMH serum levels. Furthermore,
it seems that AMH levels correlate with the extent of ovarian
dysfunction in these women, as represented by elevated LH
or T levels and an increased follicle number and/or ovarian
volume as established on ultrasound. Finally, it might be
hypothesized that the age of menopause is delayed in these
anovulatory women, which might be a direct consequence of
elevated intraovarian AMH production due to an increased
number of AMH-producing units.
TABLE 1. Clinical, endocrine, and ultrasound parameters (median and range) in normoovulatory control subjects compared to
normogonadotropic normoestrogenic anovulatory infertile women (WHO 2)
Controls (n  42) WHO 2 (n  128)
Clinical parameters
Age (yr) 29.9 (20.6–35.6) 28.9 (19.3–40.8)
BMI (kg/m2) 21.5 (18.8–24.3) 25.9 (22.1–39.8)a
Cycle duration (d) 28 (25–31) 75 (35–183)b,c
Endocrine parameters
LH (IU/liter) 3.1 (1.0–6.7) 7.0 (1.1–23.5)a
FSH (IU/liter) 6.1 (3.3–10.0) 5.5 (2.3–10.0)
Estradiol (pmol/liter) 153 (64–404) 241 (73–864)
Inhibin B (ng/liter) 113 (12–213) 129 (21–430)
Testosterone (nmol/liter) 1.5 (0.5–2.9) 2.5 (0.7–6.5)a
Androstenedione (nmol/liter) NA 14.1 (4.0–49.3)
FAI NA 5.9 (1.4–29.3)
Ultrasound parameters
Mean number of follicles (both ovaries) 14 (6–28) 24.0 (2–45)a
Ovarian volume (ml) (per ovary) NA 10.5 (2.5–22.9)
NA, Not assayed.
a P  0.01.
b P  0.001.
c Amenorrhea.
FIG. 1. Box and whisker plots depicting the AMH serum levels in
normogonadotropic anovulatory infertile women with PCOs and
those without (non-PCO), compared with normoovulatory controls.
Solid lines inside boxes depict the median AMH level, whereas the
upper and lower limits of the boxes and whiskers indicate 75th, 25th
and 95th, and 5th percentiles.
FIG. 2. Individual serum AMH concentrations vs. age in 128 WHO 2
anovulatory infertile patients (closed dots), compared with 41 nor-
moovulatory controls (open dots). Note the differences (in AMH con-
centration and slope) between the regression lines of WHO 2 and
controls.
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On histological examination it has been shown that PCOs
exhibit the same number of primordial follicles, whereas the
number of developing and subsequent atretic follicles was
doubled, compared with normoovulatory controls (25). De-
spite the increased number of developing follicles, inhibin B
serum levels (a marker for small developing follicles) were
normal in WHO 2 patients, suggesting an increased number
of atretic follicles (26). It appears that follicle development is
arrested in PCOS at the stage in which dominant follicle
selection occurs under normal conditions (27–30). Follicle
maturation arrest during later stages of development may
lead to a build up of many immature follicles, which in itself
could explain increased AMH levels. Hence, it might be
anticipated that the increased number of follicles, which are
generally present in PCOs, are the source of increased AMH
production (20).
Because AMH constitutes a marker for the number of
small follicles, its correlation with ovarian volume and the
number of follicles present in the ovary, is not surprising.
PCOs as observed during ultrasound constitute a sensitive
marker for the extent of ovarian dysfunction in anovulatory
women as well as for ovulation induction outcome (31, 32).
Although AMH serum levels were the highest in anovula-
tory patients with prominent PCOs, women without PCOs
also exhibited elevated levels. In the female, AMH is solely
synthesized by granulosa cells of preantral and small antral
follicles (4). Apparently, smaller follicles, which are not
readily detected on ultrasound, do significantly contribute to
serum AMH levels. Therefore, AMH might even constitute
a more sensitive marker of ovarian dysfunction in WHO 2
patients than PCO on ultrasound. Indeed, AMH serum levels
correlated well with other parameters indicative for the ex-
tent of ovarian dysfunction such as elevated LH and T
concentrations.
Unfortunately, AMH serum concentrations were not sig-
nificantly correlated with outcome parameters of ovulation
induction using gonadotropins in those women who previ-
ously failed clomiphene citrate ovulation induction. Simi-
larly, pregnancy rates and miscarriage rates were similar in
patients with moderately and severely elevated AMH serum
levels. Hence, elevated AMH serum levels are not associated
with adverse treatment outcome, indicating a limited pre-
dictive power of AMH levels in these patients. It seems
therefore that the clinical relevance of AMH serum concen-
trations is limited in women in whom clomiphene citrate
ovulation induction previously failed.
In PCOS patients, aromatase activity may be decreased
because follicles from PCOs do not produce large amounts
of E2. It has been shown that follicular fluid has a potent
inhibitory effect on E2 production in PCOS (33, 34). This
follicular fluid-derived inhibitor decreases aromatase activ-
ity by suppressing the P450 aromatase mRNA expression in
follicles of PCOS patients (35). Because AMH serum con-
centrations do correlate with serum levels of T, AD, and
SHBG and only weakly with E2 concentrations, it might be
speculated that AMH might constitute this follicular fluid-
derived inhibitory factor. Indeed, exogenous AMH did in-
hibit the biosynthesis of aromatase in cultured rat granulosa
cells (36). Moreover, in PCOS women an inverse relationship
between E2 and AMH serum levels has been previously
established (20).
A surprising finding constitutes the difference in relative
decline in AMH serum levels with increasing age between
normal controls and WHO 2 patients, suggesting that the
latter group might reach menopause later in life. Because
FIG. 3. Scatterplot depicting the relationship between the individual
AMH serum concentrations and LH, T, and the mean follicle number,
respectively, in WHO 2 anovulatory women. Correlation coefficients
and Spearman ranks (r) and their respective significance levels (P)
are shown in the boxes in the upper right corner.
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AMH levels correlate with the number of early antral folli-
cles, which might in turn represent the size of the resting pool
of follicles, AMH may constitute a marker for ovarian aging
(9, 13). Hence, increased intraovarian AMH production in
PCOs may slow down the process of primordial follicle re-
cruitment and thus retard depletion of the primordial follicle
pool. Although it has been reported that cycle irregularities
and hormonal profiles improve with increasing age (37–39),
data regarding the age of menopause in these women are
lacking. However, menopausal age in these women is dif-
ficult to establish because most of them will regulate their
cycles up to advanced age using oral contraceptive pills.
Whether AMH can be used as a reliable marker in PCOS
should be further substantiated. Moreover, the challenging
concept of retarded ovarian aging in PCOS needs further
confirmation by properly designed longitudinal follow-up
studies.
In conclusion, serum AMH concentrations are elevated in
WHO 2 women, which appears to be related to the increased
number of small preantral and early antral follicles, espe-
cially in those patients exhibiting PCOs. Because AMH con-
centrations correlated well with other clinical, endocrine, and
ultrasound parameters indicative of ovarian dysfunction in
these patients, AMH may constitute a novel marker for the
extent of the disease. Elevated AMH serum levels in WHO
2 and especially PCOS patients might indicate an increased
ovarian reserve.
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